Market Exclusive

Analyst Activity – Mizuho Raises Its Price Target On Adamas Pharmaceuticals (NASDAQ:ADMS) to $48.00

Analyst Ratings For Adamas Pharmaceuticals (NASDAQ:ADMS)

Today, Mizuho raised its price target on Adamas Pharmaceuticals (NASDAQ:ADMS) to $48.00 per share.

There are 6 buy ratings on the stock.

The current consensus rating on Adamas Pharmaceuticals (NASDAQ:ADMS) is Buy (Score: 3.00) with a consensus target price of $40.80 per share, a potential 91.55% upside.

Some recent analyst ratings include

Recent Insider Trading Activity For Adamas Pharmaceuticals (NASDAQ:ADMS)
Adamas Pharmaceuticals (NASDAQ:ADMS) has insider ownership of 29.00% and institutional ownership of 69.24%.

Recent Trading Activity for Adamas Pharmaceuticals (NASDAQ:ADMS)
Shares of Adamas Pharmaceuticals closed the previous trading session at with shares trading hands.

Exit mobile version